αvβ1 integrin-IN-1 (TFA)

• UNSPSC Description:

  αvβ1 integrin-IN-1 TFA (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. Antifibrotic effects[1].

• Target Antigen:

  Integrin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/αvβ1-integrin-in-1-tfa.html

• Purity:

  98.04

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)|H2O : 5 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(O)[C@H](CC1=CC=C(NC(CCCCNC(N)=N)=O)C=C1)NC([C@H]2N(S(=O)(C3=CC=CC=C3)=O)CCC2)=O.OC(C(F)(F)F)=O

• Molecular Weight:

  672.67

• References & Citations:

  [1]Reed NI, et al. Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors. ACS Med Chem Lett. 2016 Aug 30;7(10):902-907.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported